The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Future treatment priorities for high-risk MDS
Yishai Ofran, MD, Rambam Health Care Campus, Haifa, Israel, discusses the future research priorities in the myelodysplastic syndromes (MDS) field. Specifically, novel agents that decrease the inflammation process within the bone marrow. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
